Biphenyl and biphenyl-analogous compounds as integrin antagonists
First Claim
Patent Images
1. A compound of the formula:
-
whereinR1 is hydrogen or alkyl having 1-6 carbon atoms;
or a physiologically acceptable salt thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to 2-Mesitylsulfonylamino-3-{3′[(pyridinylamino)methyl][1,1-biphenyl]-4-yl}propanoic acid, pharmaceutical compositions thereof, their preparation, their use in the treatment of cancer, arteriosclerosis, restenosis, osteolytic disorders, ophthalmic disorders, and their use as integrin antagonists. The compounds according to the invention have the formula (I):
-
Citations
12 Claims
-
1. A compound of the formula:
-
wherein R1 is hydrogen or alkyl having 1-6 carbon atoms;
or a physiologically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
or a physiologically acceptable salt thereof.
-
-
4. A pharmaceutical composition comprising at least one compound according to any one of claims 1-3 and an inert, non-toxic, pharmaceutically suitable excipient or solvent.
-
5. A method for inhibiting angiogenesis and/or for treating a disorder selected from the group consisting of osteolytic diseases, arteriosclerosis, restenosis after percutaneous transluminal angioplasty and/or stenting, rheumatoid arthritis and ophthalmia, said method comprising administering to said patient an effective amount therefor of at least one compound according to any one of claims 1-3.
-
6. The method according to claim 5, which is for inhibiting angiogenesis.
-
7. The method according to claim 5, which is for treating osteolytic diseases.
-
8. The method according to claim 5, which is for treating osteoporosis.
-
9. The method according to claim 5, which is for treating arteriosclerosis.
-
10. The method according to claim 5, which is for treating restenosis after percutaneous transluminal angioplasty and/or stenting.
-
11. The method according to claim 5, which is for treating rheumatoid arthritis.
-
12. The method according to claim 5, which is for treating ophthalmia.
Specification